Information about Aclidinium
Aclidinium is a synthetic anticholinergic agent that is used as an inhalant for treatment of acute bronchospasm due to chronic bronchitis or emphysema.
Liver safety of Aclidinium
Aclidinium has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Mechanism of action of Aclidinium
Aclidinium (a" kli din' ee um) is a synthetic quaternary ammonium anticholinergic which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings, decreasing bronchial smooth muscle contractions and alleviating bronchospasm in patients with chronic obstructive pulmonary disease (COPD). Aclidinium has potent activity against muscarinic acetylcholine type 3 (M3) receptors which are found in bronchial smooth muscle. Aclidinium is rapidly hydrolyzed in plasma, so that any actively absorbed drug is unlikely to cause major systemic side effects. Its quaternary ammonium structure also decreases its ability to cross lipid membranes such as the blood brain barrier.
FDA approval information for Aclidinium
Aclidinium was approved for use in the United States in 2012 as a respiratory inhalant and indications include maintenance treatment of bronchospasm associated with chronic bronchitis and emphysema. Aclidinium is available in a dry powder inhaler under the brand name Tudorza Pressair.
Dosage and administration for Aclidinium
The typically recommended dose in adults is 1 inhalation (400 mcg) twice daily.
Side effects of Aclidinium
The common side effects of typical anticholinergic agents (such as dryness of the mouth and eyes, decreased sweating, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety and restlessness) are uncommon in patients treated with aclidinium by inhaler. Aclidinium use can cause paradoxical bronchospasm. Anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.